Researchers at Baylor College of Medicine and Rice University have received a $2.3 million Breakthrough Award from the ...

Olema Oncology plans to start a Phase III trial studying palazestrant with a CDK4/6 inhibitor from Novartis in mid-2025.

A study from researchers at the University of Michigan and the University of California San Diego has shed light on a ...

A phase 2 study for patients with HR-positive, HER2-negative metastatic breast cancer will be evaluating alisertib plus ...

On Nature published the results of an innovative breast cancer research project from the Netherlands. This study, the SONIA ...

The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ ...

The "Metastatic Triple-Negative Breast Cancer (mTNBC)- Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about 10+ ...

Top Forbes | SHOOK financial advisors and Wall Street investment firms have pledged more than $500,000 toward development of ...

Barbara O’Brien, MD, discusses the next steps of the phase 2 TBCRC049 study for the treatment of patients with HER2-positive ...

Olema Pharmaceuticals, Inc. (OLMA), a clinical-stage biopharmaceutical company, Monday announced a new clinical trial collaboration ...

Flatiron Health today announced their planned presence at this year’s San Antonio Breast Cancer Symposium (SABCS), including four accepted abstracts for poster presentation and a Flatiron ...